Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Meloxicam

            Therapeutic Area: Neurology Product Name: Anjeso

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 30, 2020

            Details:

            The data published virtually this year by the ASCRS supports the use of ANJESO® administered preoperatively as part of an Enhanced Recovery After Surgery protocol to patients prior to undergoing colorectal surgery.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Meloxicam

            Therapeutic Area: Neurology Product Name: Anjeso

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Vizient

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 20, 2020

            Details:

            Baudax Bio has entered into a Pharmacy Supplier Agreement with Vizient, Inc. effective as of July 1, 2020, to offer ANJESO (meloxicam) injection, a non-opioid option for managing moderate to severe pain.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Orphenadrine Citrate,Aspirin,Caffeine

            Therapeutic Area: Neurology Product Name: Orphengesic Forte

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 16, 2020

            Details:

            U.S. Food and Drug Administration approved the company’s Supplemental Abbreviated New Drug Application for Orphengesic Forte, over two months ahead of the scheduled goal date.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Monomethyl Fumarate

            Therapeutic Area: Neurology Product Name: Bafiertam

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 16, 2020

            Details:

            BAFIERTAM™ (monomethyl fumarate), a novel fumarate with a similar profile as Vumerity®, will be commercially available September 1, 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Acetaminophen/Paracetamol,Aspirin,Caffeine

            Therapeutic Area: Neurology Product Name: Vanquish

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 14, 2020

            Details:

            DSE Healthcare Solutions recharges its legacy brand VANQUISH® to meet the needs of today's consumer with the launch of VANQUISH® DIGITAL HEADACHE™ Brand Pain Reliever.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bupivacaine

            Therapeutic Area: Neurology Product Name: Exparel

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: DePuy Synthes Sales Inc.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination July 02, 2020

            Details:

            The agreement between the two companies to jointly market and promote the use of EXPAREL® for orthopedic procedures in the United States will terminate on January 2, 2021.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rimegepant

            Therapeutic Area: Neurology Product Name: Nurtec

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 16, 2020

            Details:

            Key presentations, including new analyses, highlight NURTEC clinical benefits including rapid and sustained efficacy with a single dose, low rescue medication use, long-term safety in patients with cardiovascular risk factors and concomitant preventive migraine medications.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rintatolimod

            Therapeutic Area: Neurology Product Name: Ampligen

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 15, 2020

            Details:

            Ampligen®, the first drug ever to receive commercial approval in any country as a treatment for severe ME/CFS, has achieved its next important regulatory step having received import clearance from Argentina's (ANMAT), Argentina's equivalent to the FDA.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Meloxicam

            Therapeutic Area: Neurology Product Name: Anjeso

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 15, 2020

            Details:

            ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing. It was approved by the U.S. Food and Drug Administration (FDA) on February 20, 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Apomorphine Hydrochloride

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 15, 2020

            Details:

            Sunovion Pharmaceuticalsannounced today that Health Canada has approved KYNMOBI™ (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD).

            PharmaCompass